Kirby McInerney LLP Reminds Lifecore Biomedical, Inc. (LFCR) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Lifecore Biomedical, Inc. for alleged deficiencies in financial reporting and internal controls, impacting the company's share price and financial statements [1][2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Lifecore securities from October 7, 2020, to March 19, 2024, with a deadline of September 27, 2024, for lead plaintiff applications [1]. - Allegations include Lifecore maintaining deficient internal controls, resulting in inaccurate financial statements that require restatement [3]. - The company’s remediation efforts regarding these deficiencies were deemed ineffective, impairing its ability to file timely reports with the SEC [3]. Group 2: Financial Impact - Between September 2022 and February 2024, Lifecore's share price declined due to disclosures about material weaknesses in internal controls and delays in SEC filings [2]. - The lawsuit claims that Lifecore's financial position and prospects were materially overstated as a result of these issues [3].